Cardio Diagnostics CEO Details India Expansion and Medicare Progress in BioMedWire Podcast

Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to transform cardiovascular disease prevention and early detection through precision medicine, as highlighted by CEO and Co-Founder Dr. Meesha Dogan in a recent appearance on The BioMedWire Podcast. The company, which leverages epigenetics, genetics, and artificial intelligence, is making significant strides in both domestic and international markets.

During the podcast, Dogan outlined Cardio Diagnostics’ expansion into India through strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs. These collaborations aim to bring the company’s innovative cardiovascular tests to one of the world’s largest and most diverse populations, addressing a critical need for accessible, personalized cardiac care. India faces a growing burden of cardiovascular disease, and Cardio Diagnostics’ AI-driven approach could help identify at-risk individuals earlier and more accurately than traditional methods.

On the regulatory front, Dogan provided an update on the company’s progress through the Medicare reimbursement process. She confirmed that CPT coding and payment steps have been completed, moving the company closer to widespread adoption. However, coverage determination remains underway, a key milestone that, once achieved, could significantly expand patient access to Cardio Diagnostics’ tests. The company is focused on demonstrating the clinical utility and cost-effectiveness of its technology to secure broader insurance coverage.

Cardio Diagnostics’ core technology, an AI-driven Integrated Genetic-Epigenetic Engine, analyzes genetic and epigenetic markers to assess cardiovascular risk. This precision medicine approach moves beyond traditional risk factors, offering a more personalized assessment that can guide preventive strategies and treatments. The company’s tests are designed to be accessible and scalable, with the potential to integrate into routine clinical practice.

The podcast appearance comes at a pivotal time for the company as it navigates the complex healthcare landscape. The emphasis on India expansion reflects a strategic move to tap into emerging markets with high unmet needs, while the Medicare progress underscores the company’s commitment to making its tests available to the U.S. elderly population, which is particularly vulnerable to cardiovascular disease.

Cardio Diagnostics’ focus on prevention and early detection aligns with broader healthcare trends emphasizing value-based care and population health management. By identifying high-risk individuals before they experience a cardiac event, the company’s technology could reduce healthcare costs and improve outcomes. The use of artificial intelligence to integrate complex biological data marks a significant advancement in the field of cardiovascular medicine.

As the company continues to develop its commercial infrastructure and pursue regulatory approvals, its progress will be closely watched by investors and healthcare providers alike. The podcast discussion provides a comprehensive overview of Cardio Diagnostics’ strategy and the potential impact of its technology on global cardiovascular health.